Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
dcw
An Open Letter to Highmark and Independence Blue Cross
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
FDA Gives Accelerated Approval to New ALS Treatment
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
Dr. Weisman participates in FDA Advisory Committee
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
ANA administers first lecanemab infusion in PA
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
